The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.
An article from
Dive Brief
//
Gene editing
The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.
Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
Lilly reports new data on PCSK9 base editing gene therapy from Verve buyout
Chamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62% - Eli L
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
Pharmalittle: We're reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
Gene-editing drugs are opening a new frontier in medicine
Eli Lilly Highlights Positive Foundayo Data At Obesity Conference - Eli Lilly (NYSE:LLY)
Eli Lilly says next-generation weight loss drug clears crucial obesity trial
Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
Pharmalittle: We're reading about a Lilly obesity drug trial, statistics for an Alzheimer's drug, and more
Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a…
Eli Lilly said a base editing gene therapy from its purchase of Verve Therapeutics delivered additional positive results in a…
Chamath Palihapitiya reacted on X after Eli Lilly's VERVE-102 showed strong Phase 1b LDL cholesterol reduction results.
Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of…
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects…
Eli Lilly reported that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a Phase 1…
